KR20220116154A - 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 - Google Patents

항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 Download PDF

Info

Publication number
KR20220116154A
KR20220116154A KR1020227018073A KR20227018073A KR20220116154A KR 20220116154 A KR20220116154 A KR 20220116154A KR 1020227018073 A KR1020227018073 A KR 1020227018073A KR 20227018073 A KR20227018073 A KR 20227018073A KR 20220116154 A KR20220116154 A KR 20220116154A
Authority
KR
South Korea
Prior art keywords
cells
antibody
antibody fragment
ser
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018073A
Other languages
English (en)
Korean (ko)
Inventor
얀 엔델
라이너 복스하머
도미니크 프레처
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20220116154A publication Critical patent/KR20220116154A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227018073A 2019-10-31 2020-10-30 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법 Pending KR20220116154A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
EP19206479.8 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Publications (1)

Publication Number Publication Date
KR20220116154A true KR20220116154A (ko) 2022-08-22

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018073A Pending KR20220116154A (ko) 2019-10-31 2020-10-30 항-cd19 항체 및 감마 델타 t-세포를 포함하는 항-종양 병용 요법

Country Status (23)

Country Link
US (1) US20210130461A1 (https=)
EP (2) EP4706673A2 (https=)
JP (2) JP7688025B2 (https=)
KR (1) KR20220116154A (https=)
CN (1) CN115151565A (https=)
AU (1) AU2020372646A1 (https=)
DK (1) DK4051710T3 (https=)
ES (1) ES3062643T3 (https=)
FI (1) FI4051710T3 (https=)
HR (1) HRP20251630T1 (https=)
IL (1) IL292213A (https=)
LT (1) LT4051710T (https=)
MA (1) MA69251B1 (https=)
MD (1) MD4051710T2 (https=)
MX (1) MX2022005033A (https=)
PH (1) PH12022551009A1 (https=)
PL (1) PL4051710T3 (https=)
PT (1) PT4051710T (https=)
RS (1) RS67602B1 (https=)
SI (1) SI4051710T1 (https=)
SM (1) SMT202600082T1 (https=)
TW (1) TWI883067B (https=)
WO (1) WO2021084063A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024058534A1 (ko) 2022-09-15 2024-03-21 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024058534A1 (ko) 2022-09-15 2024-03-21 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Also Published As

Publication number Publication date
RS67602B1 (sr) 2026-01-30
SI4051710T1 (sl) 2026-01-30
EP4051710B1 (en) 2025-11-26
JP7688025B2 (ja) 2025-06-03
LT4051710T (lt) 2026-03-10
MA69251B1 (fr) 2025-12-31
DK4051710T3 (da) 2025-12-15
US20210130461A1 (en) 2021-05-06
PL4051710T3 (pl) 2026-04-20
FI4051710T3 (fi) 2026-01-12
EP4051710A1 (en) 2022-09-07
IL292213A (en) 2022-06-01
TWI883067B (zh) 2025-05-11
WO2021084063A1 (en) 2021-05-06
CA3158984A1 (en) 2021-05-06
TW202131949A (zh) 2021-09-01
AU2020372646A1 (en) 2022-05-12
PT4051710T (pt) 2026-02-09
EP4706673A2 (en) 2026-03-11
PH12022551009A1 (en) 2023-03-20
HRP20251630T1 (hr) 2026-02-13
JP2022554324A (ja) 2022-12-28
MD4051710T2 (ro) 2026-04-30
JP2025134705A (ja) 2025-09-17
MX2022005033A (es) 2022-09-09
TW202547555A (zh) 2025-12-16
CN115151565A (zh) 2022-10-04
SMT202600082T1 (it) 2026-03-09
ES3062643T3 (en) 2026-04-13

Similar Documents

Publication Publication Date Title
TWI902626B (zh) 嵌合抗原及t細胞受體以及使用方法
TWI883067B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
US20240209061A1 (en) Fusion proteins and uses thereof
KR20200030337A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
EP4543468A2 (en) Dosing regimens for cd19-directed cancer immunotherapy
TWI922280B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
CA3158984C (en) Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EA050676B1 (ru) Противоопухолевая комбинированная терапия, включающая антитело к cd19 и гамма-дельта т-клетки
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
AU2020209425B2 (en) Antibody
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
CA3126869A1 (en) Antibody
HK40061606B (zh) 嵌合抗原和t细胞受体及使用的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000